Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance and chronic inflammation. Probiotics have been claimed effective in the management of obesity and type 2 diabetes mellitus. BiotiQuest™ Sugar Shift is a symbiotic formulation rationally designed for the endogenous conversion of glucose and fructose to support restoration of the human gut microbiota, modulation of intestinal glucose, and the production of anti-inflammatory metabolites.
We report the results of a 12-week, double blind, placebo-controlled study designed to evaluate Sugar Shift in Cuban T2DM patients. Clinical parameters, including fasting and 2h post-prandial glucose, hemoglobin A1c, a lipid panel, insulin, creatinine, and serum lipopolysaccharide levels were assessed. Microbiome composition was assessed by 16S amplicon sequencing of the variable region V3-V4 of the 16S rRNA gene. Metabolic biomarkers were inferred from microbiome data by Kruskal-Wallis H test and LEfSe.
Fasting glucose, Insulin, and serum LPS levels decreased significantly at day 84 as compared to day 1 in the treated group and to control group. Hb A1c remained stable in the treatment group as compared to the controls but not show significant improvement in the study period.
Microbiome analysis showed significant increase in Chao1 alpha diversity in the treated group between day 1 and day 84. Taxonomic and functional biomarkers revealed significant differences between the Day 1 and Day 84 microbiome profiles in the treatment group, primarily associated with acetate, propionate, and butyrate production.
Our results indicate that Sugar Shift can be a suitable adjunct therapy to standard of care therapy in the management of T2DM based upon the improvement in key inflammatory and insulin resistance markers. These results were interpreted as an indication of favorable microbiome changes during the course of the treatment for 12 weeks.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN48974890
Funding Statement
The author received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This trial was evaluated and approved under the Hermanos Ameijeiras Ethic Committee for Clinical Investigation and The Hermanos Ameijeiras Scientific Council. The Sugar Shift Probiotic supplements were also evaluated and approved for their use by the Ethical Committee at the National Institute of Nutrition of Cuba and The Cuba Ministry of Health.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying the results presented in the study are available from Martha Carlin. Email martha.carlin{at}thebiocollective.com
